These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35603335)

  • 1. Atypical infantile-onset Pompe disease with good prognosis from mainland China: A case report.
    Zhang Y; Zhang C; Shu JB; Zhang F
    World J Clin Cases; 2022 Apr; 10(10):3278-3283. PubMed ID: 35603335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants.
    Chan MY; Jalil JA; Yakob Y; Wahab SAA; Ali EZ; Khalid MKNM; Leong HY; Chew HB; Sivabalakrishnan JB; Ngu LH
    Orphanet J Rare Dis; 2023 Aug; 18(1):231. PubMed ID: 37542277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newborn screening for Pompe disease in Italy: Long-term results and future challenges.
    Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB
    Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.
    Fukuhara Y; Fuji N; Yamazaki N; Hirakiyama A; Kamioka T; Seo JH; Mashima R; Kosuga M; Okuyama T
    Mol Genet Metab Rep; 2018 Mar; 14():3-9. PubMed ID: 29124014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment.
    Yang CF; Liu HC; Hsu TR; Tsai FC; Chiang SF; Chiang CC; Ho HC; Lai CJ; Yang TF; Chuang SY; Lin CY; Niu DM
    Am J Med Genet A; 2014 Jan; 164A(1):54-61. PubMed ID: 24243590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review.
    Schoser B; Raben N; Varfaj F; Walzer M; Toscano A
    Mol Genet Metab Rep; 2024 Jun; 39():101085. PubMed ID: 38698877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Mutation Causing Severe Infantile-Onset Pompe Disease Responsive to Enzyme Replacement Therapy.
    Moravej H; Amirhakimi A; Showraki A; Amoozgar H; Hadipour Z; Nikfar G
    Iran J Med Sci; 2018 Mar; 43(2):218-222. PubMed ID: 29749992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
    Matsuoka T; Miwa Y; Tajika M; Sawada M; Fujimaki K; Soga T; Tomita H; Uemura S; Nishino I; Fukuda T; Sugie H; Kosuga M; Okuyama T; Umeda Y
    Mol Genet Metab Rep; 2016 Dec; 9():98-105. PubMed ID: 27896132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of newborn screening for Pompe disease in Japan.
    Sawada T; Kido J; Sugawara K; Momosaki K; Yoshida S; Kojima-Ishii K; Inoue T; Matsumoto S; Endo F; Ohga S; Hirose S; Nakamura K
    Orphanet J Rare Dis; 2021 Dec; 16(1):516. PubMed ID: 34922579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region.
    Al-Hassnan Z; Hashmi NA; Makhseed N; Omran TB; Al Jasmi F; Teneiji AA
    Orphanet J Rare Dis; 2022 Oct; 17(1):388. PubMed ID: 36303251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
    Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
    Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center.
    Kim MS; Song A; Im M; Huh J; Kang IS; Song J; Yang A; Kim J; Kwon EK; Choi EJ; Han SJ; Park HD; Cho SY; Jin DK
    Korean J Pediatr; 2019 Jun; 62(6):224-234. PubMed ID: 30360039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Update on Late-Onset Pompe Disease.
    Labella B; Cotti Piccinelli S; Risi B; Caria F; Damioli S; Bertella E; Poli L; Padovani A; Filosto M
    Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand.
    Ngiwsara L; Wattanasirichaigoon D; Tim-Aroon T; Rojnueangnit K; Noojaroen S; Khongkraparn A; Sawangareetrakul P; Ketudat-Cairns JR; Charoenwattanasatien R; Champattanachai V; Kuptanon C; Pangkanon S; Svasti J
    BMC Med Genet; 2019 Sep; 20(1):156. PubMed ID: 31510962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients.
    Al-Hassnan ZN; Khalifa OA; Bubshait DK; Tulbah S; Alkorashy M; Alzaidan H; Alowain M; Rahbeeni Z; Al-Sayed M
    Mol Genet Metab Rep; 2018 Jun; 15():50-54. PubMed ID: 30023291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.